AVMX-116 is under clinical development by Avirmax and currently in Phase I for Diabetic Macular Edema. According to GlobalData, Phase I drugs for Diabetic Macular Edema have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVMX-116’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVMX-116 is under development for the treatment of choroidal neovascularization (CNV), diabetic macular edema (DME) and diabetic macular retinopathy (DMR). The drug candidate comprises a recombinant adeno-associated virus (AAV) vector encoding therapeutic gene. It is being developed based on the BAC-to-AAV technology platform.
Avirmax, Inc ( Avirmax) is a biotechnology services company which innovate, develop and manufacture adeno-associated virus mediated biotherapeutic. Avirmax is headquartered in the US.
For a complete picture of AVMX-116’s drug-specific PTSR and LoA scores, buy the report here.